Frontiers in pharmacology · 2026
Chinese botanical drugs for mitigating epidermal growth factor receptor-targeted therapy-associated cutaneous toxicity: immune mechanisms and translational pathways.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lu Lu, Yu Hui, Yu Xinyang, Ren Wanlei
Аннотация
BACKGROUND: Therapies targeting the epidermal growth factor receptor (EGFR) cause a spectrum of cutaneous toxicities that can compromise quality of life, treatment adherence, and cancer-treatment continuity. Persistent and phenotype-specific toxicities create a need for evidence-based adjunctive interventions.
PURPOSE: Our aim was to appraise product-specific clinical and mechanistic evidence for Chinese botanical drugs in EGFR-targeted therapy-associated cutaneous toxicity and to define priorities for translational development.
METHODS: We conducted a structured narrative search of PubMed, Web of Science Core Collection, and Scopus from inception to 7 May 2026. Evidence was classified by the highest supporting design, from controlled human studies to indirect non-EGFR or computational evidence. We appraised directness, internal validity, product characterisation, outcome measurement, precision, and reporting completeness.
RESULTS AND DISCUSSION: Direct human evidence for defined Chinese botanical drugs remains insufficient to establish clinical efficacy. Available studies are limited by small samples, heterogeneous products, variable background care, and incomplete reporting. EGFR-specific experimental studies provide low-certainty support for barrier injury, inflammatory amplification, and phenotype-relevant mechanisms. Evidence from non-EGFR models, isolated metabolites, and network analysis remains hypothesis-generating.
CONCLUSION: Defined Chinese botanical drugs should be evaluated only as adjuncts to standard supportive care. Progress will require standardised products, phenotype-stratified trials, prespecified patient-relevant and mechanistic outcomes, and complete reporting of safety and anticancer-treatment continuity.
PURPOSE: Our aim was to appraise product-specific clinical and mechanistic evidence for Chinese botanical drugs in EGFR-targeted therapy-associated cutaneous toxicity and to define priorities for translational development.
METHODS: We conducted a structured narrative search of PubMed, Web of Science Core Collection, and Scopus from inception to 7 May 2026. Evidence was classified by the highest supporting design, from controlled human studies to indirect non-EGFR or computational evidence. We appraised directness, internal validity, product characterisation, outcome measurement, precision, and reporting completeness.
RESULTS AND DISCUSSION: Direct human evidence for defined Chinese botanical drugs remains insufficient to establish clinical efficacy. Available studies are limited by small samples, heterogeneous products, variable background care, and incomplete reporting. EGFR-specific experimental studies provide low-certainty support for barrier injury, inflammatory amplification, and phenotype-relevant mechanisms. Evidence from non-EGFR models, isolated metabolites, and network analysis remains hypothesis-generating.
CONCLUSION: Defined Chinese botanical drugs should be evaluated only as adjuncts to standard supportive care. Progress will require standardised products, phenotype-stratified trials, prespecified patient-relevant and mechanistic outcomes, and complete reporting of safety and anticancer-treatment continuity.